Taro earnings
This article was originally published in The Tan Sheet
Executive Summary
Hawthorne, N.Y.-based firm cites advertising expenses in support of ElixSure cough/cold and Kerasal moisturizer lines as a reason for an approximate 55% reduction in first-quarter net earnings to $5 mil. Overall sales declined approximately 7% to $84.1 mil., Taro reported April 26. The costs were incurred prior to the product lines' March divestment, the company maintains. Taro turned over North American marketing and distribution rights for the lines to Alterna in March (1"The Tan Sheet" March 7, 2005, p. 11)...
You may also be interested in...
Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.